Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Interest Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Ratios

Marker Therapeutics (MRKR) Cash from Discontinued Operations (2022 - 2023)

Marker Therapeutics (MRKR) has disclosed Cash from Discontinued Operations for 2 consecutive years, with 62938.0 as the latest value for Q4 2023.

Quarterly Cash from Discontinued Operations rose 97.14% to 62938.0 in Q4 2023 from the year-ago period, while the trailing twelve-month figure was 6098899.0 through Dec 2023, changed N/A year-over-year, with the annual reading at 6098899.0 for FY2023, 11.73% down from the prior year.
Cash from Discontinued Operations for Q4 2023 was 62938.0 at Marker Therapeutics, up from 260281.0 in the prior quarter.
The five-year high for Cash from Discontinued Operations was 62938.0 in Q4 2023, with the low at 2985556.0 in Q2 2023.